To tamp the sustainable and sound development foundation of the Company in the future, the Company has invested more than 8% of sales revenue in research & development. In 2018, it invested more than RMB 64 million in research & development, accounting for 11.34% of sales revenue, with the new products under research up more than 30. The Company has set up 3 institutions (Product Commission, Chengdu Research Institute, and Luzhou Research Institute) and 1 subsidiary (Feidelidi Biopharmaceutical (America) Co., Ltd.), to specialize in research & research and innovation work. The Company is provided with Waters high performance liquid chromatograph, Agilent high performance liquid chromatograph, Agilent gas chromatograph, Malvin laser particle size tester, and other complete research & development instruments and equipment. Currently, its wholly-owned subsidiary Feidelidi Biopharmaceutical (America) Co., Ltd. has comprehensively developed the new product research & development and entrusted an overseas research & development company to dock the work, and also has successfully developed the cooperation in research & development and technology with India Blending Science Test Co., Ltd. and Japan Chemicals Co., Ltd.
Since its establishment, the Company has obtained 34 production batches, applied for 111 patents, including 39 authorized patents (others are under examination), and successively won the titles including, “National Advantageous Enterprise in Intellectual Property Rights”, “Enterprise Technology Center of Sichuan Province”, “Key Laboratory of Luzhou City in Chemical Raw Medicines” and “Academician (Expert) Workstation of Luzhou City”.